Filing Flows › Dianthus Therapeutics (DNTH) › Q3 2025 › vs Q2 2025
Dianthus Therapeutics (DNTH) Q3 2025 vs Q2 2025 (quarter over quarter)
Dianthus Therapeutics's revenue rose $203K (+105%) from $193K in Q2 2025 to $396K in Q3 2025.
Dianthus Therapeutics, Q3 2025: revenue $396K (-82% year over year), net loss $36.8M, operating cash flow −$30.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q3 2025 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $396K | $193K | $203K | +105% |
| Other income, net | $3.5M | $3.3M | $225K | +7% |
| Net loss | $36.8M | $31.6M | $5.1M | +16% |
| Costs & expenses | $40.7M | $35.1M | $5.6M | +16% |
| Operating costs | $40.7M | $35.1M | $5.6M | +16% |
| Research & development | $32.5M | $26.3M | $6.2M | +24% |
| General & admin | $8.2M | $8.9M | −$674K | -8% |
| Operating cash sources | $36.8M | $31.6M | $5.1M | +16% |
| Depreciation | $27K | $30K | −$3K | -10% |
| Share-based compensation | $5.8M | $5.7M | $88K | +2% |
| Working capital & other | $389K | $2.0M | −$1.6M | -81% |
| Cash used in operations | $30.6M | $23.9M | $6.7M | +28% |
| Net loss absorbed | $36.8M | $31.6M | $5.1M | +16% |
Questions
How much did Dianthus Therapeutics's revenue grow quarter over quarter in Q3 2025?
Dianthus Therapeutics's revenue rose $203K (+105%) from $193K in Q2 2025 to $396K in Q3 2025.